The majority of putative "disease-modifying" treatments in development for Alzheimer's
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The amyloid hypothesis of Alzheimer disease (AD) holds that the accumulation of the amyloid-β (Aβ) peptide leads to synaptic dysfunction, neurodegeneration, and ultimately symptoms (1) . The vast majority of potential disease-modifying treatments developed in recent years are directed against Aβ, including inhibitors of the synthetic enzymes γ-secretase and β-secretase, and Aβ aggregation inhibitors. However, the most elaborated anti-Aβ approach is immunotherapy, including both active vaccines to stimulate the immune system to produce its own antibodies and passive immunization through the administration of exogenous antibodies.
The advantage of active immunotherapy is long-term antibody production from short-term drug administration at limited cost. Conversely, immune response may be inconsistent or lacking, especially in older individuals, and adverse reactions-if immunologically based-may also be long-lasting. Initial experience with active vaccines was marred by an ill-fated trial of AN1792 (full-length Aβ 42 with QS-21 as adjuvant) that was halted following the occurrence of T-cell mediated meningoencephalitis in 6% of treated participants (2) . Second generation vaccines such as ACC-001 (3) (4) (5) and CAD106 (6, 7) have sought to generate anti-Aβ antibodies restricted to the N-terminus, while avoiding T-cell epitopes at the C-terminus (8, 9) .
CAD106 is the only vaccine to advance to Phase 3 and has been selected for the Alzheimer Prevention Initiative (API) APOE-ε4 homozygote study (https://clinicaltrials.gov; Identifier: NCT02565511) (10) .
In contrast to active vaccination, passive immunization has the advantages of ensuring consistent antibody titers and allowing control of adverse events by stopping treatment. The major drawbacks of monoclonal antibodies (mAbs) are the need for M A N U S C R I P T
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p. 4 repeated administrations and the associated cost of production (11) . Over the past ~15 years several mAbs have been engineered to bind and clear Aβ (Table 1) and have advanced to human trials (Table 2) . Although the testing of mAbs has been fraught with failure and confusing results, the experience gained from these trials has provided important clues to enable the development of better treatments.
Bapineuzumab
Bapineuzumab (AAB-001, Pfizer/Janssen), a humanized IgG1 anti-Aβ mAb, binds the five N-terminal residues and clears both fibrillar and soluble Aβ. In 2000, Bard et al reported that in PDAPP transgenic mice, 3D6 (the murine precursor of bapineuzumab) entered the brain, decorated plaques, and induced the Fc receptor-mediated microglialphagocytosis of Aβ deposits (12) .
Bapineuzumab was the first mAb to enter human testing after the termination of the AN1792 trial. In a Phase 1 single ascending dose trial, 0.5, 1.5, or 5 mg/kg of bapineuzumab was generally safe and well-tolerated in 30 participants with mildmoderate AD (13) . However, 3/10 participants in the highest dose group developed MRI abnormalities consistent with vasogenic edema, all of which later resolved. Two participants were asymptomatic, and one experienced mild, transient confusion. These events prompted the Alzheimer's Association Research Roundtable to convene a Workgroup in July 2010, which coined the term amyloid-related imaging abnormalities (ARIA) to refer to MR signal alterations associated with Aβ-modifying therapies, specifically ARIA-E to denote vasogenic edema/effusions and ARIA-H to indicate microhemorrhage and hemosiderosis (14) . The subsequent Phase 2 trial studied IV M A N U S C R I P T (19) . A retrospective review by two neuroradiologists of MRI scans from the Phase 2 studies revealed that 36 participants (17%) had developed ARIA-E during bapineuzumab treatment, including 15 who were undetected during the trials. 28 of these (78%) reported no associated symptoms, whereas 8 symptomatic participants reported headache, confusion, and neuropsychiatric and gastrointestinal symptoms. Incident ARIA-H occurred in 17 (47%) of the participants with ARIA-E. 13/15 participants in whom ARIA-E was detected only retrospectively had received additional study infusions while ARIA-E was present, without any associated symptoms. ARIA-E was significantly related to higher doses of bapineuzumab and APOE-ε4 status (20) .
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The results of this retrospective analysis led to the practice of using central MRI readers to assess ARIA in later AD immunotherapy programs.
The increased occurrence of ARIA-E in APOE-ε4 carriers in Phase 2 resulted in separate protocols for carriers and noncarriers in the subsequent Phase 3 program. In the Phase 2 study of mild-moderate AD, 12 weeks of solanezumab treatment yielded a dose-dependent increase in CSF free Aβ 42 , suggesting a shift in equilibria sufficient to mobilize Aβ 42 from plaques. (27) .
The first Phase 3 studies-EXPEDITION1 and 2-were 18-month trials of solanezumab 400 mg versus placebo (administered IV every 4 weeks) in 1012 and 1040 participants with mild-moderate AD (28) . The original co-primary outcomes in both studies were the ADAS-Cog11 and the ADCS-ADL (29) . After analysis of data from EXPEDITION1, the primary outcome for EXPEDITION2 was revised to the ADASCog14, in the mild AD subgroup (28) . Solanezumab did not demonstrate significant benefit for the primary outcomes in either study but showed a favorable safety profile, as the incidence of ARIA-E was 0.9% with solanezumab and 0.4% with placebo. A prespecified subgroup analysis of pooled data from EXPEDITION1 and 2 showed that in participants with mild AD, there was a 34% slowing of decline for the ADAS-cog14 and 18% for the instrumental items of the ADCS-ADL (ADCS-iADL) (23) . Therefore, a third Phase 3 trial, EXPEDITION3 (NCT01900665), was launched in July 2013, restricted to mild-stage AD. Due to the high rate of Aβ-cases in EXPEDITION1 and 2, the EXPEDITION3 trial required Aβ+ PET for eligibility.
In December 2016 at the Clinical Trials on Alzheimer's Disease (CTAD) meeting, the negative results of EXPEDITION3 were presented (30) . In 2129 participants with mild AD (confirmed by Aβ+ PET), solanezumab provided a non-significant 11% slowing of decline on the primary outcome, the ADAS-Cog14. This effect size was smaller than in the pooled subgroup analysis from EXPEDITION1 and 2. Several secondary outcomes favored solanezumab-including the Clinical Dementia Rating-Sum of Boxes (CDR-SB), Mini Mental State Examination (MMSE), ADCS-iADL-however, these analyses were not corrected for multiplicity. Solanezumab had no effect on Aβ and tau
PET biomarkers. Based on the results of EXPEDITION3, the development of solanezumab was discontinued for dementia.
Solanezumab's excellent safety profile and encouraging trends in the exploratory analyses in mild AD led to its inclusion in two secondary prevention trials, which are continuing in the hope that earlier intervention may yield more substantial benefit. The were balanced between treatment groups, and only one case of ARIA-E was reported in a APOE-ε4 homozygote receiving the high-dose.
These data were interpreted as supporting the testing of crenezumab at even higher doses in prodromal to mild AD (confirmed by Aβ+ PET). A Phase 3 study (NCT02670083) is ongoing in prodromal-to-mild AD participants (MMSE 22-30), using a higher dose of crenezumab (38) . Participants are randomized to receive IV crenezumab or placebo every 4 weeks for 100 weeks, and the primary outcome measure is the CDR-SB.
Crenezumab is also being evaluated in a secondary prevention paradigm as part of an API trial of 300 cognitively normal presenilin 1 (PS1) carriers from the world's largest early-onset AD kindred in Antioquia, Colombia (NCT01998841) (10).
Ponezumab
Ponezumab (PF-04360365, Pfizer), a humanized IgG2 mAb, targets the C-terminus of The most common adverse effects were ARIA, which occurred at higher levels than in any previous anti-Aβ mAb study. ARIA-E was observed at some point during the trial in 0 participants in the placebo group, compared with 1 (3%), 2 (6%), 11 (37%), and 13 (41%) participants receiving 1, 3, 6 and 10 mg/kg aducanumab, respectively, with increased incidence in APOE-ε4 carriers. Of the 27 participants who developed ARIA-E,
(56%) continued treatment (50).
Based on the promising interim analysis of the Phase 1b study, in August 2015
Biogen launched two identical 18-month pivotal Phase 3 studies to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by the CDR-SB. Each is enrolling 1350 participants with prodromal or mild AD, as confirmed by Aβ+ PET (NCT02477800 and NCT02484547). 
Efficacy and Safety of mAbs

Targets of Anti-Aβ mAbs
The lack of efficacy thus far with anti-Aβ mAbs may bolster the case against the amyloid hypothesis of AD (52) . However, encouraging results with some antibodies make it equally difficult to dismiss this hypothesis altogether. Converging evidence over the past
two decades has suggested that the most neurotoxic species of Aβ is the soluble oligomer (1,53), which has emerged as the central target for disease-modifying treatments, including mAbs. Moreover, transgenic mouse models have suggested that therapeutic interventions reducing fibrillar Aβ at the cost of augmenting soluble species could actually be harmful (54) , although mAbs that target fibrils may also target oligomers. In this regard, the clearance of fibrillar Aβ on a PET scan is perhaps not an essential goal of treatment but may occur as an epiphenomenon to the clearance of oligomers.
As reviewed by Montoliu-Gaya and Villegas (8), mAbs directed against the Nterminus of Aβ may be most effective in clearing the toxic aggregated species of Aβ.
Transgenic mouse models have demonstrated that these antibodies inhibit Aβ aggregation and disaggregate pre-existing Aβ fibrils (12, 55, 56) . However, as described by Lu et al, using seeded fibril growth from brain extract and data from solid state nuclear magnetic resonance and electron microscopy, Aβ 40 monomers aggregate in oligomers and fibrils with multiples of three units, in which N-termini are exposed, while hydrophobic C-termini are inaccessible to antibodies (8, 57) . If a similar structure held true for Aβ 42 , then mAbs targeting the N-terminus would likely be most efficient in clearing Aβ oligomers. The success of N-terminal antibodies in clearing aggregated Aβ may also be related to microglial activation and phagocytosis, which is hypothesized to be a common feature of bapineuzumab, gantenerumab and aducanumab (12, 34, 50, 58) .
Thus far, a tight coupling has been observed between mAbs that target aggregated Aβ and the occurrence of ARIA. If ARIA-E is caused by increased trafficking to and clearance of fibrillar Aβ from cerebral vessels (20) , then mAbs could be designed
with conformationally specific epitopes selective for soluble aggregated species (oligomers and protofibrils) and avoid ARIA-E. Alternatively, if ARIA-E has an inflammatory component (14) , then antibodies may be designed to avoid inflammation.
In this regard, it is unclear whether the infrequency of ARIA-E with crenezumab is related to its IgG4 structure or its mid-domain epitope. Preclinical studies have
suggested that it binds all forms of Aβ, including fibrils (36) . However, more clinical testing is needed to see if it clears plaques. If in fact ARIA-E is more related to inflammation, then single-chain variable fragments (scFvs) and other structures lacking the microglia-activating Fc fragment could emerge as promising therapies (59, 60) . They may offer an alternative, non-inflammatory approach to the clearance of Aβ, potentially avoiding ARIA that occurs with complete antibodies.
Mechanism of Aβ Clearance by mAbs: Brain Entry Versus Peripheral Sink
Not fully resolved is whether brain entry of anti-Aβ mAbs is necessary, although many experts have attributed the failure of these agents to poor CNS penetration-only ∼0.1%) cross the blood-brain barrier (11) . Novel attempts to improve antibody penetration into brain have included targeting receptors on the blood-brain barrier to induce active transport of antibodies into the CNS, or delivering the genes encoding antibodies and inducing expression in the subject (8).
The "peripheral sink" hypothesis of mAbs is based on transport of Aβ across the blood-brain barrier, as well as an equilibrium between Aβ in brain and periphery (61, 62) .
By draining plasma Aβ, this equilibrium can be altered to leach Aβ from brain without any direct action of antibodies. Ponezumab exploited the peripheral sink effect-at least M A N U S C R I P T A C C E P T E D (31, 32) .
Importance of Higher Doses
The failure of anti-Aβ mAb trials has raised questions about the need for higher doses.
For solanezumab, the combination of insignificant efficacy and excellent safety begs the question of whether higher doses would have yielded significant effects for the primary outcomes (30) and whether these should still be considered for ongoing studies in preclinical AD (31, 32) . Similarly, the encouraging results with aducanumab pose a conundrum following disappointing results with other N-terminal antibodiesbapineuzumab and gantenerumab. Both antibodies share with aducanumab similar pharmacodynamic effects of fibrillar Aβ clearance on PET scans and ARIA-E, although at lower rates than aducanumab. Would higher doses of these drugs produce similar effects? (35) .
Importance of Stage of Disease
An often-cited explanation for the failure of anti-Aβ immunotherapy trials is that they are set too late in the disease process (9, 30) . Obviously, earlier intervention with a diseasemodifying treatment-including anti-Aβ mAbs-is advantageous. Less clear is whether early intervention is necessary for any treatment benefit, i.e., whether an Aβ "cascade" is initiated such that deterioration can no longer be slowed, or whether-in the setting of Unquestionably, the field is moving earlier, as a number of ongoing trials are evaluating treatment effects in prodromal (gantenerumab) or prodromal and mild AD (aducanumab, crenezumab, gantenerumab, BAN2401). And we should expect additional studies of preclinical AD to join the ongoing secondary prevention trials: A4
(solanezumab) (31), API (crenezumab) (10) , and DIAN-TU (solanezumab, gantenerumab) (32).
In conclusion, although the development of mAbs for AD has been beset by disappointing results, these failures contain important clues-and also evidence of promise. We have learned that mAbs vary considerably in how they interact with the Aβ peptide and that these differences may bear on whether they target the neurotoxic conformations-Aβ oligomers and protofibrils. These differences also impact the clearance of fibrillar Aβ and the occurrence of important side effects (ARIA-E).
Encouraging early results with high-dose aducanumab have suggested the need for higher doses of mAbs broadly. Immunotherapy trials may be set too late in diseasewhen too much Aβ has accumulated and the Aβ "cascade" is irrevocably initiated. We can expect new trials to move ever earlier in the course of AD and can expect mAbs to play a central role. 
